Dr. Nathan Bahary, gives a presentation on Biliary cancer and genetic testing guidelines for patients that may impact treatment recommendations.

Educational objectives:

Upon completion of this activity, participants should be able to:

  • Recognize the utility of adjuvant chemotherapy to reduce the risk of relapse and improve OS in biliary tumors
  • Improve patient treatment options in biliary cancer through molecular targeting
  • Improve the management of adjuvant therapy for primary resected pancreatic cancer

Reading Resources: 

  1. Primrose JN et .al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol 35, 2017 (suppl; abstr 4006)
  2. Buettner, S., van Vugt, J. L., IJzermans, J. N., & Groot Koerkamp, B. (2017). Intrahepatic cholangiocarcinoma: current perspectives. OncoTargets and Therapy, 10, 1131–1142.
  3. Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., et al. (2015). Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nature Communications, 6, 6087.
  4. Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., et al. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389(10073), 1011–1024. http://doi.org/10.1016/S0140-6736(16)32409-6
  5. Ben-Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., et al. (2015). SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology. http://doi.org/10.1200/JCO.2014.60.2219
  6. Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., et al. (2013). Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA : the Journal of the American Medical Association, 310(14), 1473–1481. http://doi.org/10.1001/jama.2013.279201

Disclosures:

Dr. Bahary has financial interests with the following any entity or entities producing health care goods or services as indicated below:

  • Research Funding: Pfizer, NewLinks Genetics
  • Advisory: Celgene
  • Coauthor on three of the reviewed abstracts

All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

Accreditation Statement: 

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (.5) continuing education units (CEU) which are equivalent to .5 contact hour.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 10/6/2017 | Last Modified On: 10/6/2017 | Expires: 10/8/2018

take cme evaluation